Organigram Global Inc. OGI

Organigram Global (NASDAQ:OGI) outlined a strategy centered on protecting its Canadian market position while increasing profitability, expanding internationally through its Sanity Group acquisition, improving manufacturing efficiency and applying stricter capital-allocation discipline. At its 2026

TORONTO, September 30, 2026--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the "Company" or "Organigram") is pleased to announce that the 2026 OG Investor Session will premiere today, September 30, 2026, at 4:00 p.m. ET on the Company's X account at https://x.com/Organigram_Inc.

TORONTO, September 02, 2026--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the "Company" or "Organigram"), Canada's #1 cannabis company by market share and a growing global cannabis platform, today announced details of its 2026 OG Investor Session.

TORONTO, August 20, 2026--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) ("Organigram" or the "Company") today announced an important milestone in its global growth strategy through the accelerated integration of Sanity Group GmbH ("Sanity") and the alignment of leadership, operations and market development activities across the combined organization.

Revenue jumped 49% to $105.8 million on Sanity acquisition.

Moby summary of Organigram Global Inc.'s Q3 2026 earnings call

International expansion drives 49% revenue surge and record profitability, with full-year guidance raised above $350 million.

OrganiGram (OGI) delivered earnings and revenue surprises of -400.00% and +12.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Organigram Global (NASDAQ:OGI) reported record third-quarter fiscal 2026 revenue and adjusted EBITDA, aided by the consolidation of Germany-based Sanity Group and improving performance in several Canadian cannabis categories. Net revenue rose 49% year over year to C$105.8 million, while adjusted EB

TORONTO, August 11, 2026--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share2 and a growing global cannabis platform following its acquisition of Sanity Group GmbH ("Sanity" or "Sanity Group"), today announced its results for the third quarter ended June 30, 2026 ("Q3 Fiscal 2026" or "Q3").

Evolus (EOLS) delivered earnings and revenue surprises of +100.00% and +2.59%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

TORONTO, August 04, 2026--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share and a growing global cannabis platform following its acquisition of Sanity Group GmbH ("Sanity"), announced today it will report earnings results for its third quarter ended June 30, 2026, on Tuesday, August 11, 2026, prior to market open.

Organigram Global Inc (NASDAQ:OGI) is one of the best CBD stocks to buy right now. Analysts expect Organigram Global shares to explode by more than 140% over the next 12 months. On May 12, Organigram Global Inc (NASDAQ:OGI) reported its March quarter results and issued guidance for 2026 revenue. The March quarter report showed net […]

OrganiGram Holdings (TSX:OGI) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. View the webcast at https://events.q4inc.com/analyst/574618022?pwd=FVnom6fM Summary Organigram Global Inc reported a challenging Q2 with a decline in net revenue to 59.8 million, primarily due to is

OrganiGram Holdings (NASDAQ:OGI) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://events.q4inc.com/analyst/574618022?pwd=FVnom6fM Summary Organigram Global Inc faced challenges in Q2 with Canadian recreational market growth slowing a

Despite a challenging quarter with revenue declines, Organigram Global Inc (OGI) remains optimistic about future growth, driven by strategic acquisitions and market leadership.

Organigram reported weaker second-quarter revenue and profitability as vape and infused pre-roll sales slowed, while the company positioned its Sanity Group acquisition as a major international growth catalyst. Key Investor TakeawaysOrganigram (NASDAQ:OGI) posted a 9% year-over-year decline in both gross revenue and net revenue during fiscal Q2 2026.

OrganiGram (OGI) delivered earnings and revenue surprises of -100.00% and -16.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Organigram Global (OGI.TO) swung to net loss in the second quarter as net revenue fell in the quarte